Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479101 · ClinicalTrials.gov registry record
NBRST: Prospective Neo-adjuvant REGISTRY Trial
A clinical trial, sponsored by Agendia.
- Completed
- Registry status
- 1,142
- Enrollment target
NCT01479101 is a clinical trial that has completed, run by Agendia. The registered enrollment target is 1,142 participants.
The verdict
NCT01479101 has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- 1,142 participants
- Enrollment target
Study Summary
The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1), a primary endpoint for neo-adjuvant endocrine therapy and a secondary endpoint for neoadjuvant chemotherapy), metastasis-free survival and relapse-free survival(secondary endpoints) in molecular subgroups, determined by the established MammaPrint, BluePrint, Targetprint and Theraprint profiles in addition to possible novel expression profiles.
Interventions
- OTHER MammaPrint 70-gene expression profile
- OTHER BluePrint 80 gene expression profile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,142 participants |
| Start Date | 2011-07 |
| Est. Completion | 2021-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01479101
The ClinicalTrials.gov registry entry for NCT01479101 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agendia, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MammaPrint 70-gene expression profile is the first listed.
NCT01479101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01479101 about?
NCT01479101 is a clinical study titled "NBRST: Prospective Neo-adjuvant REGISTRY Trial". The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1), a primary endpoint for neo-adjuvant endocrine therapy and a s...
What is the current status of trial NCT01479101?
This trial is currently completed. The enrollment target is 1,142 participants. The study started on 2011-07. Estimated completion is 2021-01.
What interventions are being tested in trial NCT01479101?
The interventions under investigation include: MammaPrint 70-gene expression profile (OTHER), BluePrint 80 gene expression profile (OTHER).
Who is sponsoring clinical trial NCT01479101?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.